Allogene Therapeutics Promotes New Chief Technical Officer
Allogene Therapeutics, Inc. (NASDAQ: ALLO), a clinical-stage biotechnology firm, has announced the promotion of Benjamin M. Beneski to Senior Vice President and Chief Technical Officer (CTO). This decision comes as the company looks to continue advancing its allogeneic CAR T (AlloCAR T) products aimed at treating cancer and autoimmune diseases.
Transitioning Leadership
Mr. Beneski's promotion marks a significant transition within the company as he takes over from Tim Moore, who has played a vital role for two years. Moore's leadership and contributions have been instrumental in progressing Allogene’s initiatives within the cell and gene therapy landscape. His departure is felt deeply, with the team expressing gratitude for his unwavering commitment and mentorship.
In his new role, Mr. Beneski will guide Allogene’s technical operations, capitalizing on his extensive experience in biologics manufacturing and process development. His expertise is anticipated to help propel the company's innovative projects and strengthen its operational framework.
Recognizing Beneski's Expertise
David Chang, M.D., Ph.D., the President and CEO of Allogene, shared his enthusiasm for this leadership change. He emphasized Mr. Beneski's instrumental role in shaping the company's manufacturing strategy, highlighting his ability to foster innovative solutions and build high-performing teams. This recognition reflects the trust placed in Beneski to lead Allogene into its next phase of growth.
A Glimpse into Mr. Beneski's Background
Mr. Beneski brings a wealth of experience to his new position. He joined Allogene in 2019 as Executive Director and Plant Manager, during which he spearheaded the design and launch of Cell Forge 1, the company's advanced manufacturing facility. His trajectory within the organization has included roles that have progressively increased in responsibility, heralding significant contributions to manufacturing support and product development.
Industry Experience
With over two decades dedicated to biologics manufacturing and technical operations, Mr. Beneski has held key positions at reputable organizations, including Vir Biotechnology and Amgen. His solid educational background, with an MBA from Northeastern University and a Chemical Engineering degree from Stevens Institute of Technology, complements his extensive industry expertise.
About Allogene Therapeutics
Headquartered in South San Francisco, Allogene Therapeutics is pioneering advances in allogeneic chimeric antigen receptor T cell (AlloCAR T) products. The company is driven by a mission to develop an innovative pipeline of “off-the-shelf” CAR T cell candidates, aiming for more reliable and scalable cell therapy options accessible to a broader patient population. Allogene aims to redefine how cell therapies are delivered, striving to make them more readily available on demand.
For further information about Allogene Therapeutics and updates on their developments, follow @AllogeneTx on social media platforms or visit their website.
Frequently Asked Questions
Who is the new Chief Technical Officer at Allogene Therapeutics?
Benjamin M. Beneski has been promoted to Chief Technical Officer.
What role did Tim Moore play in Allogene Therapeutics?
Tim Moore served as CTO for two years, contributing significantly to the company’s initiatives in cell and gene therapy.
What is Benjamin Beneski's experience in the industry?
Mr. Beneski has over 20 years of experience in biologics manufacturing, including leadership roles at Vir Biotechnology and Amgen.
What advancements does Allogene Therapeutics focus on?
Allogene Therapeutics focuses on developing allogeneic CAR T products aimed at treating cancer and autoimmune diseases.
How can I learn more about Allogene Therapeutics?
You can visit the company's website or follow them on social media for updates and information.
